Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB buoyed by strong first half; lupus ambitions undented despite PhIII upset

This article was originally published in Scrip

Executive Summary

The mid-sized European pharma company UCB is accelerating its investment in its early-stage portfolio following the continuing sales growth of its three core marketed products, and is also advancing a second potential lupus drug into Phase II trials following disappointing Phase III results reported earlier this week for its first lupus drug epratuzumab.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029394

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel